Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Intangibles (2016 - 2025)

Lineage Cell Therapeutics' Intangibles history spans 16 years, with the latest figure at $31.7 million for Q3 2025.

  • For Q3 2025, Intangibles fell 52.07% year-over-year to $31.7 million; the TTM value through Sep 2025 reached $31.7 million, down 52.07%, while the annual FY2024 figure was $46.5 million, 211445.45% up from the prior year.
  • Intangibles reached $31.7 million in Q3 2025 per LCTX's latest filing, roughly flat from $31.7 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $66.1 million in Q2 2022 to a low of $22000.0 in Q4 2023.
  • Average Intangibles over 5 years is $46.0 million, with a median of $46.6 million recorded in 2023.
  • Peak YoY movement for Intangibles: crashed 99.97% in 2023, then skyrocketed 211445.45% in 2024.
  • A 5-year view of Intangibles shows it stood at $46.8 million in 2021, then soared by 41.26% to $66.1 million in 2022, then plummeted by 99.97% to $22000.0 in 2023, then surged by 211445.45% to $46.5 million in 2024, then tumbled by 31.89% to $31.7 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Intangibles are $31.7 million (Q3 2025), $31.7 million (Q2 2025), and $46.5 million (Q4 2024).